{
    "clinical_study": {
        "@rank": "90962", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who\n      have brain metastases."
        }, 
        "brief_title": "Temozolomide in Treating Patients With Brain Metastases", 
        "completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the activity of temozolomide in patients with brain metastases.\n\n        -  Determine the toxicity of this treatment in these patients.\n\n      OUTLINE: Patients are stratified according to type of primary cancer (lung carcinoma vs\n      breast carcinoma vs malignant melanoma vs renal cell carcinoma vs colorectal carcinoma vs\n      other).\n\n      Patients receive oral temozolomide daily on days 1-7 and 15-21. Treatment repeats every 28\n      days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 180 patients (30 per stratum) will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Metastatic lesions to the brain\n\n               -  Must not require immediate radiotherapy\n\n               -  If received prior radiotherapy, must have progressive disease\n\n          -  Evaluable disease by CT scan or MRI\n\n          -  Neurologically stable\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  More than 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Hemoglobin at least 10 g/dL\n\n        Hepatic:\n\n          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n\n          -  SGOT or SGPT less than 2.5 times ULN\n\n          -  Alkaline phosphatase less than 2 times ULN\n\n        Renal:\n\n          -  Blood urea nitrogen less than 1.5 times ULN\n\n          -  Creatinine less than 1.5 times ULN\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No other concurrent nonmalignant systemic disease\n\n          -  No acute infection requiring treatment with IV antibiotics\n\n          -  HIV negative\n\n          -  No frequent vomiting or medical condition that would preclude oral medication\n             administration (e.g., partial bowel obstruction, inability to swallow)\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent hematopoietic growth factors, including epoetin alfa\n\n          -  No other concurrent biologic therapy\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy, unless evidence of disease progression\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Concurrent corticosteroids allowed if nonincreasing dose for at least 1 week prior to\n             study\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy to the brain, unless evidence of disease\n             progression\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  At least 3 weeks since prior surgery, unless evidence of disease progression, and\n             recovered\n\n        Other:\n\n          -  No other concurrent investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 5, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005954", 
            "org_study_id": "2114", 
            "secondary_id": [
                "DUMC-2114-02-12R3", 
                "NCI-G00-1798", 
                "CDR0000067934"
            ]
        }, 
        "intervention": {
            "intervention_name": "temozolomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Temozolomide"
        }, 
        "keyword": "adult tumors metastatic to brain", 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DUMC-2114-02-12R3"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Treatment of Adults With Brain Metastases With Temodar", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Henry S. Friedman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005954"
        }, 
        "responsible_party": {
            "name_title": "Henry Friedman, MD", 
            "organization": "Duke UMC"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {
        "Duke Comprehensive Cancer Center": "35.994 -78.899"
    }
}